Yow‐Ming Wang

1.8k total citations
54 papers, 1.0k citations indexed

About

Yow‐Ming Wang is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Yow‐Ming Wang has authored 54 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Immunology, 17 papers in Pediatrics, Perinatology and Child Health and 15 papers in Molecular Biology. Recurrent topics in Yow‐Ming Wang's work include Biosimilars and Bioanalytical Methods (30 papers), Pharmaceutical studies and practices (17 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Yow‐Ming Wang is often cited by papers focused on Biosimilars and Bioanalytical Methods (30 papers), Pharmaceutical studies and practices (17 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Yow‐Ming Wang collaborates with scholars based in United States, Switzerland and Germany. Yow‐Ming Wang's co-authors include Andrew Chow, Juan José Pérez Ruixo, Wojciech Krzyżański, Jim Xiao, Lin Zhou, Lanyan Fang, Jie Wang, Saileta Prabhu, Wendy S. Putnam and Yanan Zheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Yow‐Ming Wang

52 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yow‐Ming Wang United States 18 403 350 314 226 179 54 1.0k
Justin Earp United States 17 151 0.4× 231 0.7× 107 0.3× 151 0.7× 37 0.2× 36 829
Sriram Subramaniam United States 16 330 0.8× 366 1.0× 151 0.5× 694 3.1× 165 0.9× 27 1.4k
Diane D. Wang United States 14 126 0.3× 191 0.5× 115 0.4× 372 1.6× 41 0.2× 29 825
Jim Xiao United States 22 180 0.4× 703 2.0× 121 0.4× 630 2.8× 154 0.9× 53 1.4k
Amit Garg United States 18 153 0.4× 325 0.9× 417 1.3× 372 1.6× 26 0.1× 39 1.1k
Mohamed‐Eslam F. Mohamed United States 24 444 1.1× 172 0.5× 51 0.2× 450 2.0× 465 2.6× 64 2.1k
Raja Velagapudi United States 13 156 0.4× 166 0.5× 116 0.4× 79 0.3× 118 0.7× 18 628
David G. Orloff United States 17 609 1.5× 473 1.4× 306 1.0× 172 0.8× 79 0.4× 26 1.5k
Sander Bins Netherlands 17 150 0.4× 376 1.1× 51 0.2× 688 3.0× 86 0.5× 59 1.2k
Kenneth E. Truitt United States 22 554 1.4× 353 1.0× 76 0.2× 307 1.4× 45 0.3× 38 1.7k

Countries citing papers authored by Yow‐Ming Wang

Since Specialization
Citations

This map shows the geographic impact of Yow‐Ming Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yow‐Ming Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yow‐Ming Wang more than expected).

Fields of papers citing papers by Yow‐Ming Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yow‐Ming Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yow‐Ming Wang. The network helps show where Yow‐Ming Wang may publish in the future.

Co-authorship network of co-authors of Yow‐Ming Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Yow‐Ming Wang. A scholar is included among the top collaborators of Yow‐Ming Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yow‐Ming Wang. Yow‐Ming Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Ting, et al.. (2025). Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals. Clinical Pharmacology & Therapeutics. 119(2). 350–361.
2.
Guinn, Daphne, et al.. (2024). On placental and lactational transfer of IgG‐based therapeutic proteins – Current understanding and knowledge gaps from a clinical pharmacology perspective. Clinical and Translational Science. 17(10). e70049–e70049. 4 indexed citations
3.
Li, Ruo‐Jing, et al.. (2024). Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy. Journal of Inherited Metabolic Disease. 47(5). 1096–1106. 1 indexed citations
4.
Wang, Yow‐Ming, Ólanrewaju O. Okusanya, Bilal Abuasal, et al.. (2024). Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins. Clinical Pharmacology & Therapeutics. 115(3). 440–451. 6 indexed citations
5.
Wang, Yow‐Ming, et al.. (2024). Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products. The Journal of Clinical Pharmacology. 64(12). 1594–1605. 2 indexed citations
6.
Wang, Yow‐Ming, et al.. (2023). A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment. Pharmaceutical Research. 41(1). 13–27. 2 indexed citations
7.
Hon, Yuen Yi, Jie Wang, Henrietta Abodakpi, et al.. (2023). Dose selection for biological enzyme replacement therapy indicated for inborn errors of metabolism. Clinical and Translational Science. 16(12). 2438–2457. 6 indexed citations
8.
Ji, Ping, Sarah J. Schrieber, Sneha Rathi, et al.. (2023). Evaluation of Truncated AUC as an Alternative Measure to Assess Pharmacokinetic Comparability in Bridging Biologic–Device Using Prefilled Syringes and Autoinjectors. The Journal of Clinical Pharmacology. 63(12). 1417–1429.
9.
Guinn, Daphne, et al.. (2020). Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation. Therapeutic Innovation & Regulatory Science. 54(6). 1363–1371. 1 indexed citations
10.
Wang, Yow‐Ming, et al.. (2018). Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?. The AAPS Journal. 20(6). 99–99. 24 indexed citations
11.
12.
13.
Xiao, Jim, Wojciech Krzyżański, Yow‐Ming Wang, et al.. (2010). Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys. The AAPS Journal. 12(4). 646–657. 68 indexed citations
14.
Putnam, Wendy S., Saileta Prabhu, Yanan Zheng, Meena Subramanyam, & Yow‐Ming Wang. (2010). Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends in biotechnology. 28(10). 509–516. 79 indexed citations
15.
Wang, Yow‐Ming, Wojciech Krzyżański, Sameer Doshi, et al.. (2010). Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects. The AAPS Journal. 12(4). 729–740. 68 indexed citations
16.
Sekeres, Mikkael A., Hagop M. Kantarjian, Pierre Fenaux, et al.. (2010). Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 117(5). 992–1000. 54 indexed citations
17.
Ma, Peiming, Bingbing Yang, Yow‐Ming Wang, et al.. (2009). Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors. The Journal of Clinical Pharmacology. 49(10). 1142–1156. 69 indexed citations
18.
Thway, Theingi M., et al.. (2008). Experimental and statistical approaches in method cross-validation to support pharmacokinetic decisions. Journal of Pharmaceutical and Biomedical Analysis. 49(3). 613–618. 13 indexed citations
19.
Shao, Zhili, Kausik Bhattacharya, Eileen Hsich, et al.. (2005). c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo. Circulation Research. 98(1). 111–118. 106 indexed citations
20.
Peck, Ronald A., Matthew W. Harding, Yow‐Ming Wang, et al.. (2001). Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin. Journal of Clinical Oncology. 19(12). 3130–3141. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justin Earp Breakdown of academic impact, for papers by Sriram Subramaniam Breakdown of academic impact, for papers by Diane D. Wang Breakdown of academic impact, for papers by Jim Xiao Breakdown of academic impact, for papers by Amit Garg Breakdown of academic impact, for papers by Mohamed‐Eslam F. Mohamed Breakdown of academic impact, for papers by Raja Velagapudi Breakdown of academic impact, for papers by David G. Orloff Breakdown of academic impact, for papers by Sander Bins Breakdown of academic impact, for papers by Kenneth E. Truitt
Rankless by CCL
2026